Ligand Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

03.10.22	Ligand Announces Record Date and Details for Distribution for OmniAb Spin-Off (Businesswire)
24.08.22	Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI® (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (Businesswire)
08.08.22	Ligand Reports Second Quarter 2022 Financial Results (Businesswire)
02.08.22	Ligand Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Businesswire)
22.07.22	Ligand to Report Second Quarter Financial Results on August 8 (Businesswire)
29.06.22	Ligand Pharmaceuticals Appoints Jason Haas to its Board of Directors (Businesswire)
04.05.22	Ligand Reports First Quarter 2022 Financial Results (Businesswire)
19.04.22	Ligand to Report First Quarter Financial Results on May 4 (Businesswire)
08.04.22	Ligand Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
23.03.22	Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II (Businesswire)
17.02.22	Ligand Reports Fourth Quarter and Full Year 2021 Financial Results (Businesswire)
09.02.22	Ligand to Report Fourth Quarter Financial Results on February 17 (Businesswire)
22.12.21	Ligand’s Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly®) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy (Businesswire)
21.12.21	Ligand and GSK Expand Global Collaboration and License Agreement (Businesswire)
03.05.21	Ligand Reports First Quarter 2021 Financial Results (Businesswire)
22.04.21	Ligand to Report First Quarter Financial Results on May 3, 2021 (Businesswire)
03.02.21	Ligand Reports Fourth Quarter and Full Year 2020 Financial Results (Businesswire)
02.02.21	Ligand Partner Travere Therapeutics Announces Achievement of Interim Proteinuria Endpoint in the Ongoing Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis (Businesswire)
20.01.21	Ligand’s Fourth Quarter Financial Results to be Reported February 3rd (Businesswire)
13.01.21	Ligand Receives Milestone Payment from Merck (Businesswire)
21.12.20	Ligand and GSK Enter Global Collaboration and License Agreement Leveraging Icagen’s Discovery Technology to Target Neurological Disorders (Businesswire)
23.11.20	Ligand Announces Clinical and Regulatory Progress by Multiple Partners with OmniAb® Antibodies (Businesswire)
06.11.20	Ligand’s Partner Sedor Pharmaceuticals Receives FDA Approval for SESQUIENT™ for the Treatment of Status Epilepticus in Adult and Pediatric Patients (Businesswire)
30.10.20	Ligand Reports Third Quarter 2020 Financial Results (Businesswire)
23.10.20	Ligand’s Captisol Technology Plays Key Role in the Manufacture of Gilead’s Veklury, the First FDA-Approved COVID-19 Treatment (Businesswire)
20.10.20	Ligand Provides Highlights from Today’s Investor Day Event (Businesswire)
19.10.20	Ligand’s Third Quarter Financial Results to be Reported October 30th (Businesswire)
12.10.20	Ligand to Divest Vernalis Research Operations (Businesswire)
02.10.20	Ligand to Host Virtual Investor Day on October 20th (Businesswire)
01.10.20	Ligand Completes Acquisition of Pfenex Inc. (Businesswire)
30.09.20	Ligand Announces Expiration of Tender Offer for Shares of Pfenex Inc. (Businesswire)
23.09.20	Ligand Announces its Captisol Business is Positioned for Major Growth and Forecasts 2021 Captisol Material Sales of $200 Million (Businesswire)
10.09.20	Ligand Expands OmniAb® Antibody Discovery Platform Through the Acquisitions of xCella Biosciences and Taurus Biosciences (Businesswire)
01.09.20	Ligand Pharmaceuticals Management to Present at the H.C. Wainwright 22nd Annual Global Investment Virtual Conference (Businesswire)
31.08.20	Ligand Commences Previously Announced Cash Tender Offer to Acquire Pfenex Inc. (Businesswire)
25.08.20	Ligand OmniAb® Partner Immunovant Announced Positive Topline Results from Multicenter, Placebo-Controlled Phase 2a Trial of IMVT-1401 in Myasthenia Gravis (Businesswire)
10.08.20	Ligand to Acquire Pfenex Inc. (Businesswire)
03.08.20	Ligand Reports Second Quarter 2020 Financial Results (Businesswire)
16.07.20	Ligand’s Second Quarter Financial Results to be Reported August 3rd (Businesswire)
15.06.20	Ligand Announces an Expansion of Vernalis Collaboration with Servier for Research on Novel Oncology Targets (Businesswire)
01.06.20	Ligand CEO Issues Letter to Captisol Customers (Businesswire)
06.05.20	Ligand Reports First Quarter 2020 Financial Results (Businesswire)
22.04.20	Ligand’s First Quarter Financial Results to be Reported May 6th (Businesswire)
02.04.20	Ligand Completes Acquisition of Icagen Core Assets, Partnered Programs and Ion Channel Technologies (Businesswire)
06.02.20	Ligand Reports Fourth Quarter and Full Year 2019 Financial Results (Businesswire)
03.02.20	Ligand's Technologies Support and Enable Potential Coronavirus Treatments (Businesswire)
13.01.20	Ligand Enters into OmniAb® Platform License Agreement with Pandion Therapeutics (Businesswire)
09.01.20	Ligand to Report 2019 Fourth Quarter and Full Year Financial Results on February 6th (Businesswire)
23.12.19	Two Ligand Pharmaceuticals Board Members Recognized as 2019 Most Influential Corporate Directors by WomenInc. Magazine (Businesswire)
02.12.19	Ligand Enters into Worldwide OmniAb® Platform License Agreement with Sanofi (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Nestle	73.94	-0.22 %	K V
Alcon	76.32	-0.39 %	K V
Novartis	87.67	-0.42 %	K V
Swisscom	500.50	-0.50 %	K V
Swiss Life Hldg	684.20	-0.70 %	K V
Holcim	87.36	-1.93 %	K V
Logitech Intl	73.06	-2.35 %	K V
Part Grp Hldg	1’235.50	-2.83 %	K V
UBS Group	27.01	-2.91 %	K V
ABB	49.73	-3.47 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Ligand Pharmaceuticals Inc

Aktien Top/Flop

Meistgelesene Nachrichten